Cigrovski Berkovic M, Coppola A, Sesa V, Mrzljak A, Lai Q. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis. World J Gastroenterol 2024; 30(7): 759-769 [PMID: 38515954 DOI: 10.3748/wjg.v30.i7.759]
Corresponding Author of This Article
Maja Cigrovski Berkovic, MD, PhD, Assistant Professor, Department for Sport and Exercise Medicine, Faculty of Kinesiology University of Zagreb, Horvacanski zavoj 15, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 21, 2024; 30(7): 759-769 Published online Feb 21, 2024. doi: 10.3748/wjg.v30.i7.759
Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis
Maja Cigrovski Berkovic, Alessandro Coppola, Vibor Sesa, Anna Mrzljak, Quirino Lai
Maja Cigrovski Berkovic, Department for Sport and Exercise Medicine, Faculty of Kinesiology University of Zagreb, Zagreb 10000, Croatia
Alessandro Coppola, Department of Surgery, Sapienza University of Rome, Rome 00185, Italy
Vibor Sesa, Anna Mrzljak, Department of Gastroenterology and Hepatology, Liver Transplant Center, University Hospital Centre Zagreb, Zagreb 10000, Croatia
Anna Mrzljak, Department of Medicine, School of Medicine, Zagreb 10000, Croatia
Quirino Lai, General Surgery and Organ Transplantation Unit, Department of Surgery, Sapienza University of Rome, Rome 00018, Italy
Author contributions: Lai Q and Cigrovski Berkovic M contributed to the conception and design of the study; Coppola A and Lai Q contributed to the acquisition of data; Lai Q, Coppola A, and Sesa V analyzed and interpreted the data; Mrzljak A and Cigrovski Berkovic M drafted the article; Lai Q critically revised the manuscript; all authors approved the final version.
Conflict-of-interest statement: There is no conflict-of-interest for authors.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maja Cigrovski Berkovic, MD, PhD, Assistant Professor, Department for Sport and Exercise Medicine, Faculty of Kinesiology University of Zagreb, Horvacanski zavoj 15, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com
Received: November 19, 2023 Peer-review started: November 19, 2023 First decision: December 15, 2023 Revised: December 18, 2023 Accepted: January 23, 2024 Article in press: January 23, 2024 Published online: February 21, 2024 Processing time: 93 Days and 20.8 Hours
Core Tip
Core Tip: Pancreatic neuroendocrine tumors (pNETs) are a challenge to diagnose and treat. Often curative treatments are not possible and additional therapy aimed at symptom relief and tumor cell growth inhibition is warranted. Unfortunately, a significant number of pNET patients do not respond to the above-mentioned medical treatments or show resistance. Therefore, exploring the risk factors and additional therapeutics is of importance. This systematic review and meta-analysis showed that in patients with type 2 diabetes mellitus (T2DM), the risk for pNET insurgence was significantly increased. In addition, T2DM was a significant predictor of poor tumor free survival. Results on the role of metformin in the setting of diagnosis and prognosis of pNET due to paucity of data and data heterogeneity failed to show statistical relevance of its use, although there are indices that it might positively impact the progression free survival.
